28.29

1.84% -0.53

After Hours: 28.29

Atricure Inc (ATRC)

Overview News Price History Option Chain Financials Discussions Forecast

Atricure Inc stock is traded at $28.29, with a volume of 499.20K. It is down -1.84% in the last 24 hours and up +2.39% over the past month. AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Previous Close:

$28.82

Open:

$28.7

24h Volume:

499.20K

Relative Volume:

0.70

Market Cap:

$1.43B

Revenue:

$534.53M

Net Income/Loss:

$-11.45M

P/E Ratio:

-117.34

EPS:

-0.2411

Net Cash Flow:

$48.28M

1W Performance:

+0.60%

1M Performance:

+2.39%

6M Performance:

-21.79%

1Y Performance:

-13.78%

1-Day Range:

$28.01

$28.95

1-Week Range:

$28.01

$29.45

52-Week Range:

$25.52

$43.18

Atricure Inc Stock (ATRC) Company Profile

Name

Atricure Inc

Sector

Healthcare (1108)

Industry

Medical Instruments & Supplies (55)

Phone

513-755-4100

Address

7555 INNOVATION WAY, MASON, OH

Employee

1,350

Twitter

@AtriCure

Next Earnings Date

2026-05-05

Latest SEC Filings

ATRC's Discussions on Twitter

Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRC Atricure Inc	28.29	1.46B	534.53M	-11.45M	48.28M	-0.2411
ISRG Intuitive Surgical Inc	438.10	155.76B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	147.63	40.30B	21.37B	1.41B	3.07B	3.9437
ALC Alcon Inc	67.78	33.13B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	37.01	31.37B	29.14B	1.07B	1.05B	1.1956
RMD Resmed Inc	208.05	30.31B	5.54B	1.52B	1.74B	10.37

Atricure Inc Stock (ATRC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-26	Downgrade	Oppenheimer	Outperform → Perform
Feb-11-26	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-24	Resumed	JP Morgan	Overweight
Apr-23-24	Upgrade	Oppenheimer	Perform → Outperform
Oct-23-23	Initiated	JMP Securities	Mkt Outperform
Sep-29-23	Initiated	UBS	Buy
Aug-05-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Reiterated	Needham	Buy
Nov-06-20	Reiterated	Needham	Buy
Apr-07-20	Initiated	Oppenheimer	Outperform
Feb-06-20	Initiated	BTIG Research	Buy
Jan-24-20	Reiterated	Needham	Buy
Aug-13-19	Downgrade	Northland Capital	Outperform → Market Perform
Apr-12-19	Initiated	JP Morgan	Overweight
Oct-04-18	Reiterated	Needham	Buy
Aug-02-18	Reiterated	Needham	Buy
Aug-02-18	Reiterated	Stifel	Buy
Jun-18-18	Reiterated	Needham	Buy
Apr-27-18	Reiterated	Needham	Buy
Jan-16-18	Reiterated	Needham	Buy
Nov-02-17	Reiterated	Needham	Buy
Jul-28-17	Reiterated	Needham	Buy
May-30-17	Resumed	Piper Jaffray	Overweight
Jun-30-16	Resumed	JMP Securities	Mkt Outperform
Oct-28-15	Reiterated	Needham	Buy
Oct-06-15	Reiterated	Canaccord Genuity	Buy
Oct-06-15	Reiterated	Needham	Buy

View All

Atricure Inc Stock (ATRC) Latest News

May 22, 2026

Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) - GuruFocus

May 22, 2026

(ATRC) and the Role of Price-Sensitive Allocations - Stock Traders Daily

May 22, 2026

AtriCure director Karen Prange sells $85,950 in company stock By Investing.com - Investing.com Canada

May 22, 2026

AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares - Stock Titan

May 20, 2026

AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award - Stock Titan

May 20, 2026

Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares - Stock Titan

May 20, 2026

Director Kristine Johnson receives 6,144-share grant at AtriCure (ATRC) - Stock Titan

May 20, 2026

AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant - Stock Titan

May 20, 2026

AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant - Stock Titan

May 20, 2026

Director at AtriCure (ATRC) receives 6,144-share restricted stock grant - Stock Titan

May 20, 2026

[144] AtriCure, Inc. SEC Filing - Stock Titan

May 20, 2026

May 19, 2026

AtriCure Shareholders Approve Expanded Equity and Governance Plans - TipRanks

May 19, 2026

AtriCure (ATRC) stockholders back equity plan share increases and director slate - Stock Titan

May 19, 2026

AtriCure conference: New devices, EnCompass drive 2026 growth outlook - MSN

May 19, 2026

May 18, 2026

Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus

May 18, 2026

AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13 - Stock Titan

May 18, 2026

AtriCure Inc Annual Shareholders Meeting Transcript - GuruFocus

May 18, 2026

May 16, 2026

Loss-Making AtriCure, Inc. (NASDAQ:ATRC) Set To Breakeven - Moomoo

May 16, 2026

May 15, 2026

ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals - Stock Titan

May 15, 2026

Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake - Stock Titan

May 15, 2026

May 14, 2026